CTOs on the Move

Phreesia

www.phreesia.com

 
Leading healthcare organizations choose Phreesia to revolutionize their point of service. In medical groups of all sizes, Phreesia`s flexible and scalable platform drives tangible results across administrative, financial and clinical operations so that staff can focus on providing exceptional patient care.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.phreesia.com
  • 432 Park Avenue South
    New York, NY USA 10016
  • Phone: 888.654.7473

Executives

Name Title Contact Details
Ashwin Altekar
Vice President of Information Security Profile

Similar Companies

MedAccuracy

MedAccuracy is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dental Masters Laboratory

Dental Masters Laboratory is a Santa Rosa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Rothman Institute

The Rothman Institute is affiliated with Hospitals consisting of state-of-the-art facilities befitting world-class orthopaedic centers. Everything, from clinical and surgical centers, a fully equipped imaging area (with the latest MRI equipment) and a physical therapy center, to a pain management area, an orthotic center and research laboratories, libraries and an educational center is all under one roof.

GeoH

Indianapolis-based GeoH is a Software as a Service (SaaS) company that provides an end-to-end home care software solution. The company was named one of the Top Ten Home Healthcare Solutions Providers in 2020 by Healthcare Tech Outlook. The company was created by agency owners and technologists with more than 20 years of experience working in home health care and technology.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.